Navigation Links
Co-Founder Gavin MacBeath, Ph.D. Joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research
Date:5/26/2010

Gavin MacBeath, Ph.D., will be responsible for leading the MM-121 research team through Development and creating the Company’s general strategy for predictive medicine.

(PRWEB) May 26, 2010 -- Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and development of novel treatments for cancer and inflammation, today announced that Gavin MacBeath, Ph.D., one of the Company’s six founders, has been hired as a Senior Director and the Head of Translational Research.

“Gavin joining Merrimack underscores the pivotal next step of our vision to extend Network Biology beyond discovery research and apply it to clinical development of drugs. We believe translational science anchored in Network Biology is a key recipe for developing next generation drugs as we better characterize the underlying tumor biology for the patients we are treating,” says Clet Niyikiza, Ph.D., Merrimack’s Senior Vice President of Development.

Since Merrimack was founded in 2000, Dr. MacBeath has served on the faculty in the Department of Chemistry and Chemical Biology at Harvard University, where he has focused on developing technology that facilitates basic research in the area of systems biology. In this new position, Dr. MacBeath will be responsible for leading the MM-121 research team through Development and creating the Company’s general strategy for predictive medicine.

“Merrimack provides the resources and environment needed to address what I believe is the biggest challenge in biomedical research for the twenty-first century - the problem of matching patients to therapies” said Dr. MacBeath. “Research and development at Merrimack over the coming years will determine how important Network Biology is in the context of co-developing drugs and companion diagnostics that identify which patients will respond most effectively.”

Dr. MacBeath will continue to direct a research lab at Harvard Medical School and will serve as a bridge between Merrimack and Harvard’s academic community. Dr. MacBeath received his Bachelors of Science at the University of Manitoba and his doctorate in Macromolecular and Cellular Structure and Chemistry at the Scripps Research Institute.

About Merrimack
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

Contact: Kathleen Petrozzelli, Corporate Communications, 617-441-1043, kpetrozzelli(at)merrimackpharma(dot)com; Betsy Raymond Stevenson, 860-984-1424, RaymondStevenson Healthcare Comms betsy(at)raymondstevenson(dot)com

###

Read the full story at http://www.prweb.com/releases/2010/05/prweb4048344.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
2. Logical Therapeutics Co-Founder and CEO Honored with a Distinguished Investigator Award from the American College of Critical Care Medicine
3. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
4. ARUP Laboratories CEO and Co-Founder Announces Retirement
5. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
6. Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
7. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
8. Scripps Research Institute Highlights Groundbreaking Work of aTyr Pharma Scientific Co-Founder
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
11. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Co-Founder Gavin MacBeath, Ph.D. Joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research 
(Date:1/20/2017)... , January 20, 2017 ... cancer is one of leading causes of death worldwide. ... Although the number of cancer related deaths increased gradually ... Rising in incidence rate of various cancers continues to ... a research report by Global Market Insights, Inc. cancer ...
(Date:1/19/2017)... Research and Markets has announced the addition of the "Cancer ... Opportunity Analysis and Industry Forecast, 2014-2022" report to their offering. ... Cancer Biomarkers ... $15,737 million by 2022 from $6,521 in 2015, growing at a ... technologies segment accounted for more than half of the revenue share ...
(Date:1/19/2017)... and HOUSTON , Jan. 19, ... today announced the formation of its Medical/Clinical Advisory ... and industry veterans who enhance the range and ... accelerates development of its novel prenatal diagnostic tests.  ... clinical and strategic guidance for the company,s product ...
(Date:1/19/2017)... Research and Markets ... has announced the addition of the "Implantable Biomaterials ... report to their offering. Report Highlights: ... detailed analysis on current and future market trends to identify the investment ... as the base numbers Key market trends across the ...
Breaking Biology Technology:
(Date:12/16/2016)... Research and Markets has announced the addition of the ... report to their offering. ... The biometric vehicle access system market, in terms ... from 2016 to 2021. The market is estimated to be USD ... by 2021. The growth of the biometric vehicle access system market ...
(Date:12/15/2016)... Canada and BADEN-BADEN, Germany , ... a leading global financial services provider, today announced an agreement ... passive behavioural biometrics, to join forces. The partnership will enable ... mitigation strategies in compliance with local data protection regulation. ... In order ...
(Date:12/15/2016)... ... announced the addition of the "Global Military Biometrics Market 2016-2020" ... military biometrics market to grow at a CAGR of 7.5% during the ... an in-depth market analysis with inputs from industry experts. The report covers ... report also includes a discussion of the key vendors operating in this ...
Breaking Biology News(10 mins):